Biodexa Reports that Health Canada Approved Phase 2a Study of Tolimidone in Type 1 Diabetes

July 16, 2024

DENVER, Colo., Jul 16, 2024 (247marketnews.com)- Biodexa Pharmaceuticals PLC (Nasdaq:BDRX) reported that Health Canada approved a Phase 2a dose confirmation study of tolimidone in Type 1 diabetes (“T1D”), which will be an Investigator Initiated Trial (IIT) to be conducted by the University of Alberta and will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups.

Stephen Stamp, Biodexa’s CEO and CFO, stated, “We are excited to initiate our clinical program in Type 1 diabetes with the University of Alberta and build on the extensive tolimidone data package put together by Pfizer, Melior and Bukwang.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BDRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.